Skip to main content
[Preprint]. 2023 Dec 1:2023.11.30.569407. [Version 1] doi: 10.1101/2023.11.30.569407

Figure 6: Human in vitro validation of RELB and SOX4 as regulators of hepatocyte metabolic (mal)adaptation.

Figure 6:

(A) Experimental design schematic. (B) Pseudobulked TF expression profiles. Where applicable, “.1” and “.2” indicate isoforms of the same TF gene. (C) RELB’s effect sizes on gene program expression. Radius equals |Cohen’s D| if concordant directionality with human MASLD/HCC, and 0 if discordant. (D) RELB expression across human MASLD progression. (E) HCC human survival stratified RELB by expression. (F-H) Transcriptomic regulatory effects of SOX4, following (C-E). (I-L) Lipid accumulation (I; BODIPY 493), ROS accumulation (J; CellROX), nuclear p53 (K), and nuclear KI67 (L). (M) Representative microscopy images supporting (I-L) (scalebar=100μm). Survival outcome p-values calculated with log-rank test; all other p-values calculated using Mann-Whitney U test with Benjamini-Hochberg correction. * indicates p < 0.05; ** indicates p < 0.01; *** indicates p < 0.001.